Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?
- 15 April 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (8) , 3122-3130
- https://doi.org/10.1182/blood-2003-07-2500
Abstract
Human leukocyte antigen (HLA) class I antigen defects may have a negative impact on the growing application of T-cell-based immunotherapeutic strategies for treatment of leukemia. Therefore in the present study, taking advantage of a large panel of HLA class I allele-specific human monoclonal antibodies, we have compared HLA class I antigen expression on leukemic cells with that on autologous and allogeneic normal cells. Down-regulation of HLA-A and/or -B allospecificities was present in the majority of the patients studied. However, down-regulation did not affect all HLA class I alleles uniformly, but was almost exclusively restricted to HLA-A allospecificities and to HLA-B allospecificities which belong to the HLA-Bw6 group. The latter allospecificities, at variance from those that belong to the HLA-Bw4 group, do not modulate the interactions of leukemic cells with natural killer (NK) cells. Therefore, our results suggest that the selective down-regulation of HLA-A and HLA-Bw6 allospecificities associated with HLA-Bw4 preservation provides leukemic cells with an escape mechanism not only from cytotoxic T lymphocytes (CTLs), but also from NK cells. As a result T-cell-based immunotherapeutic strategies for leukemia should utilize HLA-Bw4 alloantigens as restricting elements since a selective HLA-Bw4 allele loss would provide leukemic cells with an escape mechanism from CTLs, but would increase their susceptibility to NK cell-mediated lysis.Keywords
This publication has 26 references indexed in Scilit:
- Specificity and functional characteristics of anti‐HLA‐A mAbs LGIII‐147.4.1 and LGIII‐220.6.2Tissue Antigens, 2003
- Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effectBlood, 2002
- Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferonHuman Immunology, 2002
- CML vaccines as a paradigm of the specific immunotherapy of cancerBlood Reviews, 2000
- Comparative expression of major histocompatibility complex (MHC) antigens on CD5+ and CD5− B cells in patients with chronic lymphocytic leukaemia (CLL)European Journal Of Cancer, 1998
- ON IMMUNOLOGICAL MEMORYAnnual Review of Immunology, 1996
- Human tumor antigens recognized by T lymphocytes.The Journal of Experimental Medicine, 1996
- Hla Class I Antigens in Human TumorsAdvances in Cancer Research, 1995
- Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodiesTissue Antigens, 1983
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978